ECM
EFTR

Evolution Capital Management’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Evolution Capital Management’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$226K Hold
21,115
– – 0.78% 25
2022
Q3 		$302K Hold
21,115
– – 0.44% 20
2022
Q2 		$750K Buy
+21,115
New +$1.28M 1.12% 11

Other funds holding EFTR

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Evolution Capital Management's EFTR Position: Q4 2022 in Review

Evolution Capital Management held its eFFECTOR Therapeutics, Inc. Common Stock (EFTR) position steady in Q4 2022 at 21,115 shares worth $226K. The position accounts for 0.78% of the portfolio, ranked #25.

Evolution Capital Management first reported a position in EFTR in Q2 2022 and has held it in 3 quarters since. The position peaked at $750K in Q2 2022. 30 funds tracked by Wall St. Rank hold EFTR as of Q4 2022.

  • Evolution Capital Management held 21,115 shares of eFFECTOR Therapeutics, Inc. Common Stock worth $226K as of Q4 2022.
  • Evolution Capital Management left its eFFECTOR Therapeutics, Inc. Common Stock share count unchanged in Q4 2022.
  • eFFECTOR Therapeutics, Inc. Common Stock made up 0.78% of Evolution Capital Management's portfolio in Q4 2022, its #25 holding.
  • Evolution Capital Management first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q2 2022 and has held it in 3 quarters since.
  • Evolution Capital Management's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $750K in Q2 2022.
  • 30 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Evolution Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.